je.st
news
Alexion: 2 Global Drug Rollouts, But Upside Already Priced In
2015-12-06 11:18:40| Biotech - Topix.net
Alexion is highly overvalued, even assuming best case peak sales projections of $1B for Strensiq, $1B for Kanuma, and $5B for Soliris. Payer risk for high-priced drugs isn't going away and orphan drug companies can't expect to keep getting a free pass.
Tags: in
global
drug
priced
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||